NEW MOLECULES I DIABETES

Abstract

Without doubt, at present, diabetology is one of the most active fields of research with unexpected results of a surprising occurrence. As witnesses but as real participants in this scientific act as well, we feel obliged to permanently underline everything that is new and the benefits of every novelty both for the patient and from a financial point of view.

The novelty turned into reality this time is the incretinic therapy including two big therapeutic families: GLP-1 receptor agonists and DPP-4 inhibitors. At present we are already working for our patients with 5 and 10μg exenatide administered twice a day and with sitagliptine 100mg / day respectively.